US equities |
NVDA $221.30 ▼-3.16% MU $914.13 ▼-4.10% AAPL $342.96 ▲+0.50% AMD $570.82 ▼-5.73% META $737.54 ▼-3.27% MSFT $533.69 ▼-1.80% TSLA $367.16 ▼-2.15% SPCX $152.16 ▼-2.80%
FinancialContent

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

58.99 +2.42 (+4.28%)
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? ↗
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains. 
Via The Motley Fool
News headline image
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts ↗
Royalty Pharma (NASDAQ:RPRX) executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China,... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? ↗
Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead. 
Via The Motley Fool
Royalty Pharma (NASDAQ:RPRX) Hits Perfect Technical Rating with Breakout Setup ↗
Via Chartmill
Royalty Pharma (NASDAQ:RPRX) Beats Q2 Revenue Estimates, Raises Full-Year Guidance ↗
Via Chartmill
News headline image
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to present at upcoming investor conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today ↗
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annualized basis producing an average annual return of 18.08%. Currently, Royalty Pharma has a market... 
Via Benzinga
News headline image
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
From Royalty Pharma plc
Via GlobeNewswire
News headline image
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today ↗
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annualized basis producing an average annual return of 40.75%. Currently, Royalty Pharma has a market... 
Via Benzinga
News headline image
Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years ↗
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market... 
Via Benzinga
News headline image
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript ↗
Royalty receipts surged 14% as guidance raised for second consecutive quarter. 
Via The Motley Fool
Topics Earnings
News headline image
Royalty Pharma Q2 Earnings Call Highlights ↗
Royalty Pharma (NASDAQ:RPRX) raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its... 
Via MarketBeat
Topics Earnings
News headline image
Royalty Pharma reports second quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma declares third quarter 2026 dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (N... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
Royalty Pharma has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.3%, reaching $55.73 per share. This performan... 
Via StockStory
Topics Supply Chain
News headline image
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean ↗
Mattel is a global toy and entertainment company behind brands like Barbie, Hot Wheels, and Fisher-Price, serving families worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
Royalty Pharma’s first quarter results surpassed Wall Street’s revenue and adjusted EBITDA expectations, driven by robust growth across its diversified royal... 
Via StockStory
Topics Earnings
News headline image
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗
Centerra Gold operates integrated mining projects in North America and Turkey, generating revenue from gold, copper, and molybdenum sales. 
Via The Motley Fool
News headline image
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗
Preformed Line Products designs and manufactures network hardware for utilities and telecoms across global infrastructure markets. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Royalty Pharma to present at upcoming investor conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript ↗
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >